Mesoporous bioactive glasses (MBGs) represent a significant advancement in bioactive glass technology, combining the well-established osteoconductive and osteoinductive properties of traditional bioactive glasses with the structural precision provided by highly ordered mesoporosity. Their characteristic architecture, defined by uniform pores typically ranging from a few to several tens of nanometers and exceptionally high surface areas reaching several hundred m2/g, enables enhanced drug-loading capacity, controlled therapeutic ion release, and accelerated tissue regeneration. In this work, we emphasize how the synthesis of these materials is predominantly governed by structure-directing agents, which critically influence the pore size, mesophase ordering, surface area, and structural stability. Additionally, we discuss how compositional tailoring, particularly through therapeutic ion doping with elements such as Sr, Cu, Zn, or B, can impart osteogenic, angiogenic, antibacterial, or antioxidant functionalities. Moreover, we illustrate how these functionalities can be further expanded and enhanced by employing a comprehensive suite of characterization tools to establish robust correlations between synthesis parameters, mesostructural features, and biological performance. Improving the above functionalities enables the MBGs to exhibit exceptional versatility across biomedical applications, notably in bone tissue engineering (as hierarchical or composite scaffolds), controlled drug delivery (anticancer, antibiotic, and anti-inflammatory agents), wound healing, dental therapy, and bioactive implant coatings. Finally, we acknowledge that despite their broad potential, several associated challenges remain, including the synthesis scalability, batch-to-batch reproducibility, mechanical fragility of pure MBGs, and the complexity of predicting in vivo degradation and ion-release behaviors. We believe that emerging research directions, including eco-friendly synthesis routes, stimuli-responsive smart MBGs, multifunctional theranostic platforms, and patient-specific additive manufacturing, are poised to overcome current limitations and drive the next generation of MBG-based biomedical technologies.
Vulpoi et al. (Thu,) studied this question.